Galmed Pharmaceuticals Ltd. - Ordinary Shares (NQ:GLMD)

4.630 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Galmed Pharmaceuticals Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >

Galmed Pharmaceuticals's Earnings Outlook ↗

April 29, 2022

Galmed Pharmaceuticals (NASDAQ:GLMD) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Galmed...

Via Benzinga

Galmed Pharmaceuticals Q4 2021 Earnings Conference Call On May 2, 2022 At 08:30 AM ET ↗

April 27, 2022

Galmed Pharmaceuticals (NASDAQ:GLMD) will host a conference call at 08:30 AM ET on May 2, 2022, to discuss Q4 2021 earnings results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 18, 2022

Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

25 Stocks Moving in Friday's Pre-Market Session ↗

March 18, 2022

Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study ↗

January 10, 2022

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of...

Via Benzinga

Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement ↗

November 08, 2021

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of...

Via Benzinga

26 Stocks Moving in Monday's Pre-Market Session ↗

November 08, 2021

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed...

Via Benzinga

Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial ↗

November 01, 2021

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled...

Via Benzinga

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action ↗

August 19, 2021

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER...

Via Benzinga

61 Biggest Movers From Yesterday ↗

August 03, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....

Via Benzinga

40 Stocks Moving In Monday's Mid-Day Session ↗

August 02, 2021

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:...

Via Benzinga

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial ↗

August 02, 2021

The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR...

Via Benzinga

28 Stocks Moving in Wednesday's Pre-Market Session ↗

June 09, 2021

Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

June 07, 2021

Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares jumped 64.8% to $8.04 on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) surged 60.3% to $5.93 after the company...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 08, 2021

Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle...

Via Benzinga

22 Stocks Moving in Monday's Pre-Market Session ↗

June 07, 2021

Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application...

Via Benzinga

64 Biggest Movers From Friday ↗

June 07, 2021

Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM...

Via Benzinga

Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines ↗

May 08, 2021

The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...

Via Talk Markets

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗

May 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

72 Biggest Movers From Yesterday ↗

May 07, 2021

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 19, 2021

Gainers Obalon Therapeutics (NASDAQ:OBLN) shares moved upwards by 6.04% to $2.63 during Monday's after-market session. At the close, Obalon Therapeutics's trading volume...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.